INS and polycystic ovary syndrome: The GLP1 agonist semaglutide has been shown to cause weight loss and decrease HOMA-IR, basal insulin, and fasting blood glucose in obese patients with PCOS who have previously been unresponsive to lifestyle modifications [16].